414 related articles for article (PubMed ID: 17641891)
1. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
[No Abstract] [Full Text] [Related]
2. [Chemotherapy of multiple myeloma].
Golenkov AK
Sov Med; 1991; (3):43-6. PubMed ID: 1882290
[No Abstract] [Full Text] [Related]
3. [Pneumonia caused by Salmonella in a patient with myeloma].
Fernández P; Roldán V; García MC; Gil MT; Rivas C
Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286
[No Abstract] [Full Text] [Related]
4. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
[TBL] [Abstract][Full Text] [Related]
5. [New treatment strategies for multiple myeloma].
Ozaki S
Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
[No Abstract] [Full Text] [Related]
6. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
[TBL] [Abstract][Full Text] [Related]
7. [Recent therapy for refractory myeloma].
Togawa A
Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy for multiple myeloma].
Ishida T
Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
10. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
[No Abstract] [Full Text] [Related]
11. [Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"].
Raya Sánchez JM; González Brito G; Marsá Vila L; Brito Barroso ML; Hernández Nieto L
Sangre (Barc); 1991 Oct; 36(5):434-5. PubMed ID: 1816642
[No Abstract] [Full Text] [Related]
12. [The influence of verapamil on platelet function in patients with multiple myeloma].
Sokołowska B; Dmoszyńska A; Walter-Croneck A; Wojtaszko M
Pol Merkur Lekarski; 1997 Feb; 2(8):109-10. PubMed ID: 9538652
[TBL] [Abstract][Full Text] [Related]
13. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
Lila AM; Mazurov VI; Novik AA
Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578
[No Abstract] [Full Text] [Related]
14. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
[No Abstract] [Full Text] [Related]
15. [Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
Kraj M; Dmoszyńska A; Maj S; Kowalewski J; Rostkowska J; Pogłód R; Sokołowska B; Mendek-Czajkowska E; Kurowska M; Sokołowska U
Acta Haematol Pol; 1991; 22(1):4-20. PubMed ID: 1823965
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide for the treatment of leptomeningeal multiple myeloma.
Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
[No Abstract] [Full Text] [Related]
17. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson P; Anderson K
J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
[No Abstract] [Full Text] [Related]
18. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
[No Abstract] [Full Text] [Related]
19. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]